caplacizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5308 915810-67-2

Description:

MoleculeDescription

Synonyms:

  • caplacizumab
  • ALX-0081
  • ALX-0681
  • calibvi
  • caplacizumab-yhdp
In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 30, 2018 EMA ABLYNX NV
Feb. 6, 2019 FDA ABLYNX NV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 118.35 58.42 13 260 88 50604763

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 141.70 51.66 16 328 145 64498243
ADAMTS13 activity abnormal 89.23 51.66 8 336 0 64498388
Platelet count decreased 56.64 51.66 24 320 167687 64330701

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AX07 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Other antithrombotic agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Thrombotic thrombocytopenic purpura indication 78129009 DOID:10772




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
von Willebrand factor Unclassified ANTIBODY BINDING Kd 8.51 IUPHAR DRUG LABEL

External reference:

IDSource
2R27AB6766 UNII
C3713057 UMLSCUI
CHEMBL2109624 ChEMBL_ID
DB06081 DRUGBANK_ID
D11160 KEGG_DRUG
9123 IUPHAR_LIGAND_ID
2110604 RXNORM
36266 MMSL
d09171 MMSL
784411004 SNOMEDCT_US
789447000 SNOMEDCT_US
4038197 VANDF
4038198 VANDF
017896 NDDF
C585343 MESH_SUPPLEMENTAL_RECORD_UI
9511 INN_ID

Pharmaceutical products:

None